Join PhoenixBio in Denver for OTS 2026!

PhoenixBio is heading to Denver! We're excited to announce that our team will be exhibiting at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), October 11–14, 2026, at the Colorado Convention Center. Come find us at Booth #3.

What to expect at our booth

OTS brings together the scientists advancing antisense, siRNA and other oligonucleotide therapies — many of which target the liver. That's where PhoenixBio can help. Stop by to talk with our team about:

• The PXB-mouse® – a chimeric mouse with a highly humanized liver, built to predict human-specific efficacy, pharmacokinetics and safety of liver-targeted oligonucleotides
• PXB-cells® – fresh primary human hepatocytes for in vitro screening that translates to in vivo studies

Whether you're early in discovery or preparing for IND-enabling studies, we'd love to hear about your program.

Recent Highlights: The PXB-mouse & Oligonucleotide Therapeutics

Targeting LDLR: A recent preprint from Camp4 Therapeutics demonstrated that a GalNAc conjugated ASO can target regulatory RNAs controlling LDLR expression – leading to increased LDLR on hepatocytes and reduction of LDL cholesterol in the blood stream of PXB-mice. The PXB-mouse’s humanized lipoprotein profile made it well suited for this exciting research using oligonucleotide therapies to positively regulate gene expression.

Antisense Oligonucleotides Targeting an LDLR Regulatory RNA Increase LDLR Expression and Reduce LDL-cholesterol in Vivo Gnanapradeepan et al. bioRxiv 2026.06.02.729508; doi: https://doi.org/10.64898/2026.06.02.729508

LNP Delivery in PXB-mice: Specific knockdown of human TTR was achieved in the PXB-mouse using an LNP-encapsulated siRNA. Reduced levels of TTR protein were also observed in the circulation. Use of a mouse specific TTR siRNA did not impact human levels and the opposite was also true, highlighting that robust species specificity targeting is feasible in the PXB-mouse.

Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment. Yamazaki et al, Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466

Clinical Translatable Toxicity Data: The PXB-mouse was used to investigate the toxicity of VIR-2218 (Elebsiran). VIR-2218 is a glycol nucleic acid–modified siRNA targeting HBV. PXB-mouse studies showed that VIR-2218 had significantly reduced human ALT1 elevation compared to the unmodified oligonucleotide (ALN-HBV). This positive hepatic safety profile was further validated by successful clinical studies using VIR-2218.

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials. Gane et al., J Hepatol. 2023 Oct;79(4):924-932. doi: 10.1016/j.jhep.2023.05.023

Want dedicated time with our scientists? Email us at annie.egan@phoenixbiousa.com to book a meeting at the booth. We look forward to seeing you in Denver!